{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:44:39Z","timestamp":1792104279218,"version":"4.4.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National Du Cancer","doi-asserted-by":"publisher","award":["Inca_20195"],"award-info":[{"award-number":["Inca_20195"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-22-CE14-0066"],"award-info":[{"award-number":["ANR-22-CE14-0066"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["21-ESRE-0028"],"award-info":[{"award-number":["21-ESRE-0028"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Differ"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Premortem exposure of calreticulin (CALR) on stressed cancer cells is a cardinal damage-associated molecular pattern that licenses anticancer immunity, yet its immunological sufficiency has remained difficult to define because it normally coincides with cellular stress and cell death. Here, we engineered a chemical-genetic system enabling the conditional, biotin-driven translocation of a membrane-anchored CALR chimera from the endoplasmic reticulum to the plasma membrane, thereby uncoupling CALR exposure from cytotoxicity and other hallmarks of immunogenic cell death. This reductionist approach revealed that isolated CALR surface presentation is sufficient to promote CD91\/LRP1-dependent engulfment of tumor cells by conventional dendritic cells, particularly cDC1 and cDC2, leading to enhanced dendritic cell activation, cytotoxic lymphocyte responses, and immunological memory. Across multiple syngeneic tumor models, enforced CALR exposure exerted modest standalone antitumor activity but robustly sensitized poorly immunogenic cancers to cisplatin and PD-1 blockade, culminating in T cell-dependent tumor eradication and durable protective immunity. Remarkably, concurrent inhibition of the CD47\u2013SIRP\u03b1 axis facilitated complete tumor eradication in all treated animals, highlighting the functional cooperation between eat-me and don\u2019t-eat-me signals in orchestrating antigen presentation and adaptive immune priming. These findings further suggest that maximizing the therapeutic activity of CD47 blockade may require concomitant reinforcement of pro-phagocytic signals such as CALR exposure, providing a conceptual framework for the rational design of next-generation combination immunotherapies. Collectively, these findings establish surface-exposed CALR as a cell-autonomous immunogenic signal with instructive activity for dendritic cell-mediated cross-priming and provide a tractable platform to mechanistically deconvolute immunogenic stress responses, with immediate implications for the rational design of combinatorial chemo- and immunotherapeutic regimens in preclinical and potentially clinical oncology.<\/jats:p>","DOI":"10.1038\/s41418-026-01891-7","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:56:27Z","timestamp":1792101387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A chemical-genetic system for calreticulin exposure on cancer cells reveals immune-dependent antitumor effects"],"prefix":"10.1038","author":[{"given":"Liwei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misha","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6081-9558","authenticated-orcid":false,"given":"Oliver","family":"Kepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9334-4405","authenticated-orcid":false,"given":"Guido","family":"Kroemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1682-9222","authenticated-orcid":false,"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"1891_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s41573-024-00920-9","volume":"23","author":"L Galluzzi","year":"2024","unstructured":"Galluzzi L, Guilbaud E, Schmidt D, Kroemer G, Marincola FM. Targeting immunogenic cell stress and death for cancer therapy. Nat Rev Drug Discov. 2024;23:445\u201360.","journal-title":"Nat Rev Drug Discov"},{"key":"1891_CR2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2093518","volume":"11","author":"P Liu","year":"2022","unstructured":"Liu P, Chen J, Zhao L, Hollebecque A, Kepp O, Zitvogel L, et al. PD-1 blockade synergizes with oxaliplatin-based, but not cisplatin-based, chemotherapy of gastric cancer. OncoImmunology. 2022;11:2093518.","journal-title":"OncoImmunology"},{"key":"1891_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/imr.13269","volume":"321","author":"P Liu","year":"2024","unstructured":"Liu P, Zhao L, Zitvogel L, Kepp O, Kroemer G. Immunogenic cell death (ICD) enhancers\u2014Drugs that enhance the perception of ICD by dendritic cells. Immunol Rev. 2024;321:7\u201319.","journal-title":"Immunol Rev"},{"key":"1891_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/nm1523","volume":"13","author":"M Obeid","year":"2007","unstructured":"Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini J-L, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2007;13:54\u201361.","journal-title":"Nat Med"},{"key":"1891_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.17839","volume":"28","author":"M Michalak","year":"2024","unstructured":"Michalak M. Calreticulin: endoplasmic reticulum Ca2+ gatekeeper. J Cell Mol Med. 2024;28:e17839.","journal-title":"J Cell Mol Med"},{"key":"1891_CR6","doi-asserted-by":"crossref","unstructured":"Venkatesan A, Satin LS, Raghavan M. Roles of Calreticulin in Protein Folding, Immunity, Calcium Signaling and Cell Transformation. In: Agellon LB, Michalak M (eds). Cellular Biology of the Endoplasmic Reticulum. Springer International Publishing: Cham, 2021, pp 145-62.","DOI":"10.1007\/978-3-030-67696-4_7"},{"key":"1891_CR7","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1038\/s41418-017-0044-9","volume":"25","author":"L Bezu","year":"2018","unstructured":"Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S, et al. eIF2\u03b1 phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ. 2018;25:1375\u201393.","journal-title":"Cell Death Differ"},{"key":"1891_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2005.08.032","volume":"123","author":"SJ Gardai","year":"2005","unstructured":"Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell. 2005;123:321\u201334.","journal-title":"Cell"},{"key":"1891_CR9","doi-asserted-by":"publisher","unstructured":"Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, Volkmer J et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010;2. https:\/\/doi.org\/10.1126\/scitranslmed.3001375.","DOI":"10.1126\/scitranslmed.3001375"},{"key":"1891_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cellimm.2015.12.003","volume":"300","author":"X Liu","year":"2016","unstructured":"Liu X, Li J, Liu Y, Ding J, Tong Z, Liu Y, et al. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells. Cell Immunol. 2016;300:46\u201353.","journal-title":"Cell Immunol"},{"key":"1891_CR11","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/emboj.2009.1","volume":"28","author":"T Panaretakis","year":"2009","unstructured":"Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund A, Chapman DC, et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J. 2009;28:578\u201390.","journal-title":"EMBO J"},{"key":"1891_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115277","volume":"163","author":"Q Ma","year":"2025","unstructured":"Ma Q, Lan Z, Yang Y, Sun R, Xue D, Lin X, et al. Calreticulin-driven immunogenic cell death promotes osteoclast differentiation and osteoarthritis progression via the LRP1\/Rac1 signaling. Int Immunopharmacol. 2025;163:115277.","journal-title":"Int Immunopharmacol"},{"key":"1891_CR13","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ijc.28070","volume":"133","author":"JW Hodge","year":"2013","unstructured":"Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang K-Y, Ferrone S, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133:624\u201336.","journal-title":"Int J Cancer"},{"key":"1891_CR14","doi-asserted-by":"publisher","first-page":"6169","DOI":"10.1158\/1538-7445.AM2025-6169","volume":"85","author":"A Cavaliere","year":"2025","unstructured":"Cavaliere A, Macagno M, Maione F, Amodio V, Olmo ME, Chil\u00e0 R, et al. Abstract 6169: Immunogenic cell death mediates the anticancer efficacy of high dose vitamin C. Cancer Res. 2025;85:6169.","journal-title":"Cancer Res"},{"key":"1891_CR15","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1021\/acsami.2c19311","volume":"15","author":"EM Hassan","year":"2023","unstructured":"Hassan EM, McWhirter S, Walker GC, Martinez-Rubi Y, Zou S. Elimination of cancer cells in co-culture: role of different nanocarriers in regulation of cd47 and calreticulin-induced phagocytosis. ACS Appl Mater Interfaces. 2023;15:3791\u2013803.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1891_CR16","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.molcel.2019.11.004","volume":"77","author":"P Liu","year":"2020","unstructured":"Liu P, Zhao L, Loos F, Marty C, Xie W, Martins I, et al. Immunosuppression by mutated calreticulin released from malignant cells. Mol Cell. 2020;77:748\u2013760.e9.","journal-title":"Mol Cell"},{"key":"1891_CR17","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.127239","volume":"4","author":"Sedlacek","year":"2019","unstructured":"Sedlacek, Younker AL, Zhou TP, Borghesi YJ, Shcheglova L, Mandoiu II T, et al. CD91 on dendritic cells governs immunosurveillance of nascent, emerging tumors. JCI Insight. 2019;4:e127239.","journal-title":"JCI Insight"},{"key":"1891_CR18","doi-asserted-by":"publisher","first-page":"e62621","DOI":"10.1371\/journal.pone.0062621","volume":"8","author":"C Richter","year":"2013","unstructured":"Richter C, Thieme S, Bando\u0142a J, Laugsch M, Anastassiadis K, Brenner S. Generation of inducible immortalized dendritic cells with proper immune function in vitro and in vivo. PLoS ONE. 2013;8:e62621.","journal-title":"PLoS ONE"},{"key":"1891_CR19","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1158\/2159-8290.CD-22-1338","volume":"13","author":"L Zhao","year":"2023","unstructured":"Zhao L, Liu P, Mao M, Zhang S, Bigenwald C, Dutertre C-A, et al. BCL2 inhibition reveals a dendritic cell\u2013specific immune checkpoint that controls tumor immunosurveillance. Cancer Discov. 2023;13:2448\u201369.","journal-title":"Cancer Discov"},{"key":"1891_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nmeth.1928","volume":"9","author":"G Boncompain","year":"2012","unstructured":"Boncompain G, Divoux S, Gareil N, De Forges H, Lescure A, Latreche L, et al. Synchronization of secretory protein traffic in populations of cells. Nat Methods. 2012;9:493\u20138.","journal-title":"Nat Methods"},{"key":"1891_CR21","doi-asserted-by":"crossref","unstructured":"Liu P, Zhao L, Kepp O, Kroemer G. Quantitation of calreticulin exposure associated with immunogenic cell death. Methods in Enzymology. 2020:632:1\u201313.","DOI":"10.1016\/bs.mie.2019.05.011"},{"key":"1891_CR22","doi-asserted-by":"publisher","first-page":"18545","DOI":"10.1016\/S0021-9258(19)81393-5","volume":"263","author":"T Fujiwara","year":"1988","unstructured":"Fujiwara T, Oda K, Yokota S, Takatsuki A, Ikehara Y. Brefeldin A causes disassembly of the Golgi complex and accumulation of secretory proteins in the endoplasmic reticulum. J Biol Chem. 1988;263:18545\u201352.","journal-title":"J Biol Chem"},{"key":"1891_CR23","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1083\/jcb.200302069","volume":"161","author":"AW Orr","year":"2003","unstructured":"Orr AW, Pedraza CE, Pallero MA, Elzie CA, Goicoechea S, Strickland DK, et al. Low density lipoprotein receptor\u2013related protein is a calreticulin coreceptor that signals focal adhesion disassembly. J Cell Biol. 2003;161:1179\u201389.","journal-title":"J Cell Biol"},{"key":"1891_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phanu.2026.100488","volume":"36","author":"A Altun","year":"2026","unstructured":"Altun A, Selamio\u011flu A, Gedikba\u015f\u0131 A. Biotin in health and disease: A review of its metabolic and pharmacological implications. PharmaNutrition. 2026;36:100488.","journal-title":"PharmaNutrition"},{"key":"1891_CR25","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","volume":"119","author":"DA Hume","year":"2012","unstructured":"Hume DA, MacDonald KPA. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood. 2012;119:1810\u201320.","journal-title":"Blood"},{"key":"1891_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/imr.13263","volume":"321","author":"F Ghiringhelli","year":"2024","unstructured":"Ghiringhelli F, R\u00e9b\u00e9 C. Using immunogenic cell death to improve anticancer efficacy of immune checkpoint inhibitors: From basic science to clinical application. Immunol Rev. 2024;321:335\u201349.","journal-title":"Immunol Rev"},{"key":"1891_CR27","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1007\/s00262-021-03072-6","volume":"71","author":"TM Abdullah","year":"2022","unstructured":"Abdullah TM, Whatmore J, Bremer E, Slibinskas R, Michalak M, Eggleton P. Endoplasmic reticulum stress-induced release and binding of calreticulin from human ovarian cancer cells. Cancer Immunol Immunother. 2022;71:1655\u201369.","journal-title":"Cancer Immunol Immunother"},{"key":"1891_CR28","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1182\/blood.2022016846","volume":"141","author":"C Pecquet","year":"2023","unstructured":"Pecquet C, Papadopoulos N, Balligand T, Chachoua I, Tisserand A, Vertenoeil G, et al. Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms. Blood. 2023;141:917\u201329.","journal-title":"Blood"},{"key":"1891_CR29","doi-asserted-by":"publisher","first-page":"38612","DOI":"10.1074\/jbc.M110.168294","volume":"285","author":"G Kozlov","year":"2010","unstructured":"Kozlov G, Pocanschi CL, Rosenauer A, Bastos-Aristizabal S, Gorelik A, Williams DB, et al. Structural basis of carbohydrate recognition by calreticulin. J Biol Chem. 2010;285:38612\u201320.","journal-title":"J Biol Chem"},{"key":"1891_CR30","doi-asserted-by":"publisher","first-page":"35104","DOI":"10.1074\/jbc.M113.507921","volume":"288","author":"SJ Wijeyesakere","year":"2013","unstructured":"Wijeyesakere SJ, Rizvi SM, Raghavan M. Glycan-dependent and -independent interactions contribute to cellular substrate recruitment by calreticulin. J Biol Chem. 2013;288:35104\u201316.","journal-title":"J Biol Chem"},{"key":"1891_CR31","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3390\/membranes4030630","volume":"4","author":"Y Jiang","year":"2014","unstructured":"Jiang Y, Dey S, Matsunami H. Calreticulin: roles in cell-surface protein expression. Membranes. 2014;4:630\u201341.","journal-title":"Membranes"},{"key":"1891_CR32","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-hodgkin lymphoma. Cell. 2010;142:699\u2013713.","journal-title":"Cell"},{"key":"1891_CR33","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1073\/pnas.1424907112","volume":"112","author":"M Feng","year":"2015","unstructured":"Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer J-P, Ho PY, McKenna KM, et al. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proc Natl Acad Sci USA. 2015;112:2145\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1891_CR34","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","volume":"138","author":"S Jaiswal","year":"2009","unstructured":"Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138:271\u201385.","journal-title":"Cell"},{"key":"1891_CR35","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng D, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody\u2013mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci USA. 2013;110:11103\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1891_CR36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1084\/jem.20100269","volume":"208","author":"Y Ma","year":"2011","unstructured":"Ma Y, Aymeric L, Locher C, Mattarollo SR, Delahaye NF, Pereira P, et al. Contribution of IL-17-producing gamma delta T cells to the efficacy of anticancer chemotherapy. J Exp Med. 2011;208:491\u2013503.","journal-title":"J Exp Med"},{"key":"1891_CR37","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CMT, Pryer N, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014;26:623\u201337.","journal-title":"Cancer Cell"}],"container-title":["Cell Death &amp; Differentiation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01891-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01891-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:56:28Z","timestamp":1792101388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41418-026-01891-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,15]]},"references-count":37,"alternative-id":["1891"],"URL":"https:\/\/doi.org\/10.1038\/s41418-026-01891-7","relation":{},"ISSN":["1350-9047","1476-5403"],"issn-type":[{"value":"1350-9047","type":"print"},{"value":"1476-5403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,15]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"OK is a scientific co-founder of Samsara Therapeutics. GK has been holding research contracts with Daiichi Sankyo, Eleor, Kaleido, Lytix Pharma, PharmaMar, Osasuna Therapeutics, Samsara Therapeutics, Sanofi, Sutro, Tollys and Vascage. GK is on the Board of Directors of the Bristol Myers Squibb Foundation France. GK is a scientific co-founder of everImmune, Osasuna Therapeutics, Samsara Therapeutics and Therafast Bio. GK is in the scientific advisory boards of Hevolution, Institut Servier and Rejuveron Life Sciences\/Centenara Labs AG. GK is the inventor of patents covering therapeutic targeting of aging, cancer, cystic fibrosis and metabolic disorders. GK\u2019s brother, Romano Kroemer, was an employee of Sanofi and now consults for Boehringer-Ingelheim. GK\u2019s wife, Laurence Zitvogel, has held research contracts with Glaxo Smyth Kline, Incyte, Lytix, Kaleido, Innovate Pharma, Daiichi Sankyo, Pilege, Merus, Transgene, 9\u2009m, Tusk and Roche, was on the Board of Directors of Transgene, is a cofounder of everImmune and holds patents covering the treatment of cancer and the therapeutic manipulation of the microbiota. The funders had no role in the design of the study, in the writing of the manuscript or in the decision to publish the results. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal experiments were performed in accordance with relevant institutional and national guidelines and regulations, adhered to ethics projects #2025_043 and #2025_048. All experimental procedures involving animals were reviewed and approved by the local ethics committee of Gustave Roussy Campus Cancer (CEEA IRCIV\/IGR no. 26) that is registered with the French Ministry of Research. This study did not involve human participants or identifiable human images; therefore, informed consent to participate and consent for publication were not applicable.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}